【摘要】 近年子宫内膜癌发病率呈上升趋势，且趋于年轻化。大部分的子宫内膜癌是低级别、早期子宫内膜样癌，预后良好。然而，部分低级别、早期子宫内膜样癌患者易复发且预后较差，早期识别这些高危患者有助于确定哪些患者需要额外的辅助治疗和更密切的随访。近年来CTNNB1突变被认为是此类患者潜在的复发风险因素，具有独立的预后价值，但到目前为止对于低级别、早期且伴有CTNNB1突变的子宫内膜样癌患者是否需要辅助治疗尚无明确的指南。结合收治的1例ⅠA期、低级别、伴有CTNNB1基因突变的子宫内膜样癌患者诊治情况，对该基因突变加以探讨，以期提高对具有此类突变患者的预后及后续治疗的进一步认识。更多还原

【Abstract】 The incidence of endometrial carcinoma has been increasing in recent years, and the age of onset is tends to younger. Most endometrial carcinomas are low-grade, early-stage endometrioid carcinomas(EECs) with a good prognosis. However,some patients with low-grade, early-stage EECs are prone to recurrence and have a poor prognosis. Early identification of these high-risk patients with EECs can help determine which patients need additional adjuvant therapy and closer follow-up. In recent years, CTNNB1 mutation has been considered as a potential risk factor for recurrence, which has independent prognostic value. But so far, there are no clear guidelines on whether adjuvant therapy is needed for low-grade and early-stage EECs patients with CTNNB1 mutation. Combined with a patient with an ⅠA stage, low-grade patient with CTNNB1 gene mutation in our hospital, this gene mutation is mainly discussed in order to improve clinicians′ further understanding of the prognosis and follow-up treatment of patients with such mutation.更多还原